ERBB2 and neoplasm: Then, PD-1/HER-2 bispecific antibodies could eliminate tumor cells without antigen recognition (53) Hence, the enhanced antitumor effect of PD-1 inhibitors might be more evident in HER2-overexpressing tumors.